Literature DB >> 16316952

Silent adenoma subtype 3 of the pituitary--immunohistochemical and ultrastructural classification: a review of 29 cases.

E Horvath1, K Kovacs, H S Smyth, M Cusimano, W Singer.   

Abstract

The silent adenoma subtype 3 (SAS-3) of undetermined cellular derivation is a seemingly nonfunctioning aggressive pituitary tumor with a high recurrence rate. At the time of diagnosis SAS-3s are macro- or giant adenomas particularly aggressive in young individuals, especially women. They are usually associated with mild hyperprolactinemia and are unremarkable by histology. Immunohistochemistry, demonstrating scattered immunoreactivity mostly for GH, PRL, TSH, and alpha-subunit, is not diagnostic. Presently, only TEM permits conclusive diagnosis. Ultrastructurally, the large polar adenoma cells contain abundant RER, masses of SER, extensive multipolar Golgi apparatus, and unevenly clustered mitochondria, displaced by RER and SER, which may show close spatial relationship to RER. Cell membranes often form plexiform interdigitations. Nuclear pleomorphism and nuclear inclusions are common. The 100- to 200-nm secretory granules accumulate heavily in cell processes, which is a hallmark of glycoprotein hormone cell differentiation. The endothelial cells may contain tubuloreticular inclusions. Complete surgical removal of the large often invasive tumors is difficult necessitating postoperative treatment. SAS-3 is sensitive to conventional radiation. Some tumors express somatostatin receptors and respond well to somatostatin analogues, offering long-term control in patients with residual tumor. Possible derivation of SAS-3 from rostral thyrotrophs, a cell type presently known in rodents is contemplated.

Entities:  

Mesh:

Year:  2005        PMID: 16316952     DOI: 10.1080/01913120500323514

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  23 in total

1.  [The 2017 WHO classification of pituitary tumors].

Authors:  Wolfgang Saeger
Journal:  Pathologe       Date:  2021-04-20       Impact factor: 1.011

Review 2.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 3.  Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Authors:  Odelia Cooper; Shlomo Melmed
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-22       Impact factor: 4.690

4.  MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.

Authors:  Michael E Fealey; Bernd W Scheithauer; Eva Horvath; Dana Erickson; Kalman Kovacs; Roger McLendon; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

5.  Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes.

Authors:  Yuichi Nagata; Naoko Inoshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Hiroshi Nishioka; Takeo Iwata; Katsuhiko Yoshimoto; Shozo Yamada
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

Review 6.  Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).

Authors:  Nèle Lenders; Ann McCormack
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

7.  Collision tumors of the sella: craniopharyngioma and silent pituitary adenoma subtype 3: case report.

Authors:  Olga Moshkin; Bernd W Scheithauer; Luis V Syro; Alejandro Velasquez; Eva Horvath; Kalman Kovacs
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

8.  Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas.

Authors:  Elaine Lu Wang; Zhi Rong Qian; Shozo Yamada; Md Mustafizur Rahman; Naoko Inosita; Teruyoshi Kageji; Hideko Endo; Eiji Kudo; Toshiaki Sano
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

9.  Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.

Authors:  Ozgur Mete; Karen Gomez-Hernandez; Walter Kucharczyk; Rowena Ridout; Gelareh Zadeh; Fred Gentili; Shereen Ezzat; Sylvia L Asa
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

10.  Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism.

Authors:  Bernardo Dias Pereira; Luísa Raimundo; Ozgur Mete; Ana Oliveira; Jorge Portugal; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.